Kidney Cancer Clinical Trials

Showing 1-10 of 10 items
  • Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
  • This is a randomized, open-label Phase 2 clinical trial to evaluate whether suppression of Hsp27 (Heat shock protein 27) production using OGX-427, a second-generation antisense oligonucleotide (ASO), in combination with docetaxel can prolong survival time compared to docetaxel alone in participants with locally advanced or metastatic urothelial carcinoma (UC) that are relapsed or refractory after receiving a platinum-containing regimen.
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
  • A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
  • CyberKnife Based Radiosurgery is a way to deliver large doses of radiation very accurately to a tumor. The ability of this technology to minimize radiation dose to organs adjacent to the target tumor allows a high dose to be delivered to the tumor, thus potentially increasing the efficacy of radiation treatment. Currently, radiosurgery is commonly used for brain metastases, Stage I lung cancer, spine tumors, and localized prostate cancer. The purpose of this protocol is to evaluate the role of Radiosurgery for the treatment of clinically localized primary renal cell carcinoma.
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
  • Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Kidney Cancer
  • This research study is evaluating the combination of pazopanib and everolimus in patients that have a malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective, or metastatic or locally advanced unresectable kidney cancer. In this research study the investigators are testing the safety of the combination of pazopanib and everolimus as well as to find the appropriate dose to use for further studies.
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
  • A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
  • This phase II, single-arm study was designed to evaluate the effect of MPDL3280A treatment in patients with locally advanced or metastatic urothelial bladder ca ncer. Patients will be enrolled into 1 of 2 cohorts. Cohort 1 will consist of pa tients who are treatment-naïve and ineligible for platinum-containing therapy. C ohort 2 will contain patients who have progressed during or following a prior pl atinum-based chemotherapy regimen. Patients in both cohorts will be given a 1200 mg intravenous (IV) dose of MPDL3280A on Day 1 of 21-day cycles. Treatment may continue for up to 16 cycles or 12 months, whichever is first, in the absence of toxicity or disease progression. Patients will be followed for up for 2 years. Patients who complete the initial treatment stage of up to 16 cycles may be eli gible for MPDL3280A re-treatment upon subsequent disease progression during the follow-up period and without intervening systemic anti-cancer therapy.
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
Showing 1-10 of 10 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms